scholarly journals Case Report: 1-Year Follow-Up of Vagus Nerve Stimulation in a Dog With Drug-Resistant Epilepsy

2021 ◽  
Vol 8 ◽  
Author(s):  
Junya Hirashima ◽  
Miyoko Saito ◽  
Hirotaka Igarashi ◽  
Satoshi Takagi ◽  
Daisuke Hasegawa
Keyword(s):  
Adverse Effects ◽  
Vagus Nerve ◽  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Drug Resistant ◽  
Stimulation Parameters ◽  
Term Evaluation ◽  
Drug Resistant Epilepsy

A vagus nerve stimulation (VNS) system was surgically implanted to treat drug-resistant epilepsy in a 5-year-old male Shetland Sheepdog. At regular visits during a 1-year follow-up, treatment efficacy and adverse effects were assessed, and programmable stimulation parameters were adjusted to optimize stimulation intensity while avoiding adverse effects. The frequency of generalized tonic–clonic seizures was reduced by 87% after the initiation of VNS. The owner reported that the dog regained his personality, and the quality of life of both the dog and owner improved. The only adverse effect of VNS was a cough that was controlled by adjusting stimulation parameters. There were no surgical complications or other issues with the VNS device. This is the first long-term evaluation of VNS therapy in a dog, and the results obtained suggest that gradual adjustments of VNS parameters facilitate optimum VNS dosing.

Vagus nerve stimulation in drug-resistant epilepsy: the efficacy and adverse effects in a 5-year follow-up study in Iran

2016 ◽  
Vol 37 (11) ◽  
pp. 1773-1778 ◽  
Author(s):  
Hossein Pakdaman ◽  
Ali Amini Harandi ◽  
Mehdi Abbasi ◽  
Mohammad Karimi ◽  
Mohammad Ali Arami ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Vagus Nerve ◽  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Drug Resistant ◽  
Follow Up Study ◽  
Drug Resistant Epilepsy

Vagus nerve stimulation for drug-resistant epilepsy

2019 ◽  
Vol 20 (3) ◽  
pp. 189-198 ◽  
Author(s):  
Laura Pérez-Carbonell ◽  
Howard Faulkner ◽  
Sean Higgins ◽  
Michalis Koutroumanidis ◽  
Guy Leschziner
Keyword(s):  
Vagus Nerve ◽  
Seizure Frequency ◽  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Therapeutic Option ◽  
Drug Resistant ◽  
Drug Resistant Epilepsy ◽  
Randomised Controlled

Vagus nerve stimulation (VNS) is a neuromodulatory therapeutic option for drug-resistant epilepsy. In randomised controlled trials, VNS implantation has resulted in over 50% reduction in seizure frequency in 26%–40% of patients within 1 year. Long-term uncontrolled studies suggest better responses to VNS over time; however, the assessment of other potential predictive factors has led to contradictory results. Although initially designed for managing focal seizures, its use has been extended to other forms of drug-resistant epilepsy. In this review, we discuss the evidence supporting the use of VNS, its impact on seizure frequency and quality of life, and common adverse effects of this therapy. We also include practical guidance for the approach to and the management of patients with VNS in situ.

Long-term results of vagus nerve stimulation in children and adolescents with drug-resistant epilepsy

2012 ◽  
Vol 28 (4) ◽  
pp. 621-628 ◽  
Author(s):  
Beata Majkowska-Zwolińska ◽  
Piotr Zwoliński ◽  
Marcin Roszkowski ◽  
Krzysztof Drabik
Keyword(s):  
Vagus Nerve ◽  
Children And Adolescents ◽  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Long Term Results ◽  
Drug Resistant ◽  
Drug Resistant Epilepsy

Vagus nerve stimulation for drug-resistant epilepsy: A European long-term study up to 24 months in 347 children

Epilepsia ◽  
2014 ◽  
Vol 55 (10) ◽  
pp. 1576-1584 ◽  
Author(s):  
Iren Orosz ◽  
David McCormick ◽  
Nelia Zamponi ◽  
Sophia Varadkar ◽  
Martha Feucht ◽  
...  
Keyword(s):  
Vagus Nerve ◽  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Drug Resistant ◽  
Term Study ◽  
Long Term Study ◽  
Drug Resistant Epilepsy

scholarly journals Vagus nerve stimulation therapy in people with drug-resistant epilepsy (CORE-VNS): rationale and design of a real-world post-market comprehensive outcomes registry

2021 ◽  
Vol 3 (2) ◽  
pp. e000218
Author(s):  
Arjune Sen ◽  
Ryan Verner ◽  
James P Valeriano ◽  
Ricky Lee ◽  
Muhammad Zafar ◽  
...  
Keyword(s):  
Vagus Nerve ◽  
Nerve Stimulation ◽  
Real World ◽  
Vagus Nerve Stimulation ◽  
Drug Resistant ◽  
The Core ◽  
Post Market ◽  
Drug Resistant Epilepsy

IntroductionThe Vagus Nerve Stimulation Therapy System (VNS Therapy) is an adjunctive neuromodulatory therapy that can be efficacious in reducing the frequency and severity of seizures in people with drug-resistant epilepsy (DRE). CORE-VNS aims to examine the long-term safety and clinical outcomes of VNS in people with DRE.Methods and analysisThe CORE-VNS study is an international, multicentre, prospective, observational, all-comers, post-market registry. People with DRE receiving VNS Therapy for the first time as well as people being reimplanted with VNS Therapy are eligible. Participants have a baseline visit (prior to device implant). They will be followed for a minimum of 36 months and a maximum of 60 months after implant. Analysis endpoints include seizure frequency (average number of events per month), seizure severity (individual-rated categorical outcome including very mild, mild, moderate, severe or very severe) as well as non-seizure outcomes such as adverse events, use of antiseizure medications, use of other non-pharmacological therapies, quality of life, validated measures of quality of sleep (Pittsburgh Sleep Quality Index or Children’s Sleep Habit Questionnaire) and healthcare resource utilisation. While the CORE-VNS registry was not expressly designed to test hypotheses, subgroup analyses and exploratory analysis that require hypothesis testing will be conducted across propensity score matched treatment groups, where possible based on sampling.Ethics and disseminationThe CORE-VNS registry has already enrolled 823 participants from 61 centres across 15 countries. Once complete, CORE-VNS will represent one of the largest real-world clinical data sets to allow a more comprehensive understanding of the management of DRE with adjunctive VNS. Manuscripts derived from this database will shed important new light on the characteristics of people receiving VNS Therapy; the practical use of VNS across different countries, and factors influencing long-term response.Trail registration numberNCT03529045.

Vagus nerve stimulation in drug-resistant epilepsies. Analysis of potential prognostic factors in a cohort of patients with long-term follow-up

2012 ◽  
Vol 154 (12) ◽  
pp. 2237-2240 ◽  
Author(s):  
Gabriella Colicchio ◽  
Nicola Montano ◽  
Filomena Fuggetta ◽  
Fabio Papacci ◽  
Francesco Signorelli ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Vagus Nerve ◽  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Drug Resistant ◽  
Long Term Follow Up

scholarly journals Chronic vagus nerve stimulation for drug-resistant epilepsy may influence fasting blood glucose concentration

2020 ◽  
Author(s):  
Hongyun Liu ◽  
Ping Zhan ◽  
Fangang Meng ◽  
Weidong Wang
Keyword(s):  
Body Mass Index ◽  
Blood Glucose ◽  
Vagus Nerve ◽  
Body Mass ◽  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Fasting Blood Glucose ◽  
Drug Resistant ◽  
Drug Resistant Epilepsy

Abstract Background Cervical vagus nerve stimulation (VNS) has been widely accepted as adjunctive therapy for drug-resistant epilepsy and major depression. Its effects on glycemic control in humans were however poorly understood. The aim of our study was to investigate the potential effects of VNS on fasting blood glucose (FBG) in patients with drug-resistant epilepsy. Methods Patients with drug-resistant epilepsy who had received VNS implants at the same hospital were retrospectively studied. Effects on FBG, weight, body mass index and blood pressure were evaluated at 4, 8 and 12 months of follow-up. Results 32 subjects (11 females/21males, 19±9 years, body mass index 22.2±4.0 kg/m 2 ) completed 12-month follow-up. At the 4 months, there were no significant changes in FBG concentrations from baseline to follow-up in both Sham-VNS (4.89±0.54 vs. 4.56±0.54 mmol/L, N=13, p=0.101) and VNS (4.80±0.54 vs. 4.50±0.56 mmol/L, N=19, p=0.117) groups. However, after 8 (4.90±0.42 mmol/L, N=32, p=0.001) and 12 (4.86±0.40 mmol/L, N=32, p=0.002) months of VNS, FBG levels significantly increased compared to baseline values (4.52±0.54 mmol/L, N=32). Changes in FBG concentrations at both 8 (R 2 =0.502, N=32, p<0.001) and 12 (R 2 =0.572, N=32, p<0.001) months were negatively correlated with baseline FBG levels. Conclusions Our study suggests that chronic cervical VNS elevates FBG levels with commonly used stimulation parameters in patients with epilepsy.

Sign in / Sign up

Export Citation Format

Share Document